Tizanidine Tablet
Product Images NDC 51655-603

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 51655-603). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 603 20 Master Bottle Label Approval Rev A 02 21)

Label (51655 603 20 Master Bottle Label Approval   Rev A 02 21)
NDC 51655-603-20 is a bottle of 20 tablets of Tizanidine 4mg, a medication used to treat muscle spasms caused by certain conditions such as multiple sclerosis or spinal cord injury. The dosage should be followed as per package insert, and the tablets should be stored in a controlled room temperature between 15-30°C. It is important to keep the tablets out of children's reach and store them in the original container. The tablets should not be interchanged with Tizanidine capsules. The repackaging of the medication has been done by Northwind Pharmaceuticals. The tablet contains 4.576mg tizanidine hydrochloride USP, which is equivalent to 4mg tizanidine base. The medication has been manufactured by Dr. Reddy's Laboratories Limited. The lot number and the expiration date of the medication are not available.*
FDA Label Image

Fig1 (Fig1)

Fig1 (Fig1)
This text displays a chart of plasma Tzanidine concentration in ng/mL based on different dosing scenarios of 4mg Tzanidine tablets and capsules with or without food. The chart is presented over time, with hours from dosing displayed at the bottom. Additionally, the text includes a reference to a company or organization called "2500 Eoiir Mamar RAS Nemar JRes! BN BA% Rak Gar azwaa", but this is likely a result of errors and is not a useful description of the text content.*
FDA Label Image

Fig2 (Fig2)

FDA Label Image

Fig3 (Fig3)

Fig3 (Fig3)
The text is describing a study related to the improvement in Ashworth Score. The drug used in the study is Zanidine at a mean dose of 28.6 mg. The endpoints of the study were at Week 3 and End of Maintenance (Week 7). The last observation was carried forward for analysis.*
FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.